Oruka Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 02/06/24 | FY 02/05/24 | FY 12/31/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $0.0 |
| Operating income | -$122.1 | -$88.1 | — | — | -$7.3 |
| Net income | -$105.4 | -$83.7 | — | — | -$5.3 |
| Balance Sheet | |||||
| Total debt | — | — | — | — | $0.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$88.4 | -$58.0 | — | — | -$5.0 |
Shares outstanding 66.2M · Free float 49.8%
Annual filing data through FY ended December 31, 2025; float as of September 22, 2026.